Analyst Price Target is $7.25
▲ +655.76% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for TELA Bio in the last 3 months. The average price target is $7.25, with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 655.76% upside from the last price of $0.96.
Current Consensus is
Moderate Buy
The current consensus among 4 polled investment analysts is to moderate buy stock in TELA Bio. This rating has held steady since February 2025, when it changed from a Buy consensus rating.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Read More